Shionogi & Co., Ltd.
Regarding Additional Investment in ViiV Healthcare Ltd. and Its Application as an Equity-Method Affiliate
Shionogi & Co., Ltd. plans to invest USD 2.125 billion (approximately JPY 334.793 billion) to increase its voting rights ratio in ViiV Healthcare Ltd. from 10.0% to 21.7%, thereby achieving application as an equity-method affiliate (to be acquired by the end of March 2026).
Key Figures
- Acquisition Price: USD 2.125 billion (approximately JPY 334,793 million)
- Voting Rights Ratio: 10.0% before acquisition, 21.7% after acquisition
- Scheduled Share Acquisition Completion Date: By the end of March 2026
AI要約
Background and Purpose of the Investment
Shionogi & Co., Ltd. considers "liberation from the threat of infectious diseases" a critical issue and focuses on HIV infection. Since 2001, it has collaborated with ViiV Healthcare Ltd. and GSK plc to successfully develop integrase inhibitors. This additional investment aims to strengthen the partnership with ViiV and contribute to global HIV treatment and prevention.
Outline of the Agreement and Future Outlook
The company will invest USD 2.125 billion to acquire newly issued shares of ViiV, increasing its voting rights ratio to 21.7% and applying the equity method of accounting for ViiV as an affiliate. The share acquisition is planned to be executed by the end of March 2026, with a minimal impact on consolidated results for the fiscal year ending March 2026. Profit contributions are expected from the fiscal year ending March 2027 onward.
